Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355637 | 0.84 | GSK3B (0.37) | GSK3BDDB1CRBNKDM4ELIMK1 | |
| SCHEMBL28752449 | 0.76 | GSK3B (0.59) | GSK3BKDM4ELIMK1SCN9AALDH1A1 | |
| SCHEMBL30506312 | 0.76 | GLS (0.56) | GPR3DDB1CRBNKDM4EHTR2A | |
| SCHEMBL628648 | 0.76 | KDM4E (0.42) | GPR3KDM4ELIMK1ALDH1A1HPGD | |
| SCHEMBL147947 | 0.76 | GLS (0.56) | GPR3DDB1CRBNKDM4EHTR2A | |
| SCHEMBL8535608 | 0.75 | HPGD (0.47) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL3655093 | 0.75 | PRKCI (0.41) | GSK3BDDB1CRBNKDM4ELIMK1 | |
| SCHEMBL29585194 | 0.75 | KDM4E (0.41) | GPR3DDB1CRBNKDM4EHTR2A | |
| SCHEMBL21000228 | 0.75 | DDB1 (0.49) | GSK3BDDB1CRBNKDM4ESCN9A | |
| SCHEMBL17910321 | 0.75 | KDM4E (0.41) | GPR3DDB1CRBNKDM4EHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE37781-E1 | VIRICIDES, PROTEASE INHIBITOR | DUPONT PHARMACEUTICALS COMPANY | 2002-07-02 | — | — | US | claimed |
| US-5877170-A | VIRICIDES | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | claimed |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4603488-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2025-08-20 | — | — | EP | disclosed |
| CN-120035587-A | Novel indazole derivative or pharmaceutically acceptable salt thereof and use thereof | 高丽大学校产学协力团 | 2025-05-23 | — | — | CN | disclosed |
| EP-3617213-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-02-19 | — | — | EP | disclosed |
| US-20240262817-A1 | QUINAZOLINE DERIVATIVES TARGETING R(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4402127-A1 | AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE | UCL Business Ltd (GB) | 2024-07-24 | — | — | EP | disclosed |
| US-12036292-B2 | Heterobiaryl compounds and imaging agents for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
| US-20080058401-A1 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008024945-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPV1 AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007076092-A2 | NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070010555-A1 | Indazole having analgesic activity | AZIENDE CHIM. RUIN. ANGEL. FRA. A.C.R.A.F. S.P.A. (IT) | 2007-01-11 | — | — | US | disclosed |
| EP-1622892-A1 | INDAZOLES HAVING ANALGESIC ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004101548-A1 | INDAZOLE HAVING ANALGESIC ACTIVITY , | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2004-11-25 | — | — | WO | disclosed |
| US-5447905-A | Postemergence herbicides | DOWELANCO (US) | 1995-09-05 | — | — | US | disclosed |
| US-5264560-A | Alkylation of monoazo dye | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262817-A1 | QUINAZOLINE DERIVATIVES TARGETING R(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2 | MBNL1, HNRNPUL1, HNRNPUL2 | GSK3B 4050/4885GPR3 3013/4885DDB1 116/4885 |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | GSK3B 229/4885GPR3 1014/4885DDB1 2283/4885 |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | GSK3B 2860/4885GPR3 3500/4885DDB1 110/4885 |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | ERBB2, ERBB3, ARRB1 | GSK3B 189/4885GPR3 193/4885DDB1 1948/4885 |
| US-12036292-B2 | Heterobiaryl compounds and imaging agents for imaging huntingtin protein | HTT, HYPK, ATXN2L | GSK3B 1640/4885GPR3 1156/4885DDB1 668/4885 |
| US-20070010555-A1 | Indazole having analgesic activity | ACHE, CYP3A43, RPL35A | GSK3B 2637/4885GPR3 443/4885DDB1 4087/4885 |
| US-20080058401-A1 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | TRPV1, TRPA1, OPRK1 | GSK3B 2630/4885GPR3 143/4885DDB1 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.